Saniona

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

See press release here

Saniona to Participate in Stifel and Jefferies Virtual Investor Conferences in November

See press release here

Saniona expands executive team with appointments of Chief Financial Officer, Chief Communications Officer and Chief Human Resources Officer

See press release here

s

See allNews

Proprietary Pipeline Read more about our Proprietary Pipeline

We have a broad portfolio of potential drug candidates in preclinical or clinical stages.

Tesomet for treatment of Prader-Willi Syndrome and Hypothalamic Obesity

SAN711 for the treatment of rare neuropathic disorders

SAN903 for rare inflammatory and fibrotic disorders